EXTENDED REPORT

Adalimumab in the therapy of uveitis in childhood

Sabine Biester¹, Christoph Deuter¹, Hartmut Michels², Renate Haefner², Jasmin Kuemmerle-Deschner³, Deshka Doycheva¹ and Manfred Zierhut¹

¹ Department of Ophthalmology, University of Tuebingen, Tuebingen, Germany
² Rheumatic Childrens’ Hospital, Garmisch-Partenkirchen, Germany
³ Department of Pediatrics I, University of Tuebingen, Tuebingen, Germany

Correspondence to:
Correspondence to:
Prof. Manfred Zierhut
MD, Department of Ophthalmology, University of Tuebingen, Schleichstr. 12, 72076 Tuebingen, Germany; Manfred.zierhut{at}med.uni-tuebingen.de

Purpose: Chronic anterior uveitis in children often takes a serious course. Despite various immunosuppressive drugs some children do not respond sufficiently and there is a high risk of them becoming seriously disabled. Anti-TNF alpha therapy has been shown by our group and others to be mostly ineffective (Etanercept) or partly effective (Infliximab) with the risk of anaphylactic reactions. Here we report on 18 young patients treated with Adalimumab (Humira®), a complete humanised anti-TNF alpha antibody.

Methods: We retrospectively analysed 18 patients, who were treated with Adalimumab (20–40 mg, every 2 weeks, when ineffective every week); 17 had juvenile idiopathic arthritis, one was without detectable underlying disease. The age at onset of arthritis varied from 0.5–15 years and for uveitis from 2–19 years. Patients were included when the previous anti-inflammatory therapy had been ineffective. It consisted of systemic steroids (n = 18), Cyclosporin A (n = 18), Methotrexate (n = 18), Azathioprine (n = 12), Mycophenolate mofetil (n = 4), Cyclophosphamide (n = 2), Leflunomide (n = 3), Etanercept (n = 8) and Infliximab (n = 5). The grading for uveitis was: (a) effective: no relapse or more than two relapses less than before treatment, (b) mild: one relapse less than before treatment, (c) no response: no change in relapse rate and (d) worsening: more relapses under treatment than before. The grading for arthritis (depending on the clinical findings), using three out of six parameters of the ACR PED Criteria, was: effective, mild, no response, worsening.

Results: For arthritis (n = 16) the response to Adalimumab was effective in 10 of 16 patients, mild in three patients, three did not respond. For uveitis (n = 18) Adalimumab was effective in 16, mild in one child, and one patient did not show any effect. After a very good response initially a shorter application time had to be used to maintain the good anti-inflammatory effect in one child. Additional immunosuppressive treatment was used in seven of the effectively treated children. Due to elevation of liver enzymes in one patient, who also took MTX, Adalimumab had to be discontinued. No anaphylactic reactions or increased frequency of infections since start of Adalimumab treatment was reported.

Conclusions: For our group of children with long lasting disease our results show that Adalimumab was effective or mildly effective against the arthritis in 81%, but in uveitis in 88%. While these results regarding arthritis are comparable with other TNF-alpha blocking drugs (Etanercept), Adalimumab seems to be much more effective against uveitis than Etanercept. Anaphylactic reactions, found in a previous study from our group after Infliximab treatment, were not seen with Adalimumab. The necessary dosage and the treatment period, which probably have to be defined individually for each patient, remain unclear.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

BJO at a glance

Creig Hoyt
Br. J. Ophthalmol. 2007 91: 269a. [Extract] [Full Text] [PDF]

Adalimumab in the therapy of uveitis in childhood

Ahmad M Mansour
Br. J. Ophthalmol. 2007 91: 274-276. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Tynjala, P, Vahasalo, P, Honkanen, V, Lahdenne, P (2009). Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Ann Rheum Dis 68: 552-557 [Abstract] [Full Text]  
• Foster, H., Ramanan, A. V. (2009). 'The eyes have it!' The need to improve awareness and access to early ophthalmological screening for juvenile idiopathic arthritis associated uveitis. Rheumatology (Oxford) 48: 330-331 [Full Text]  
• Furst, D E, Keystone, E C, Kirkham, B, Fleischmann, R, Mease, P, Breedveld, F C, Smolen, J S, Kalden, J R, Burmester, G R, Braun, J, Emery, P, Winthrop, K, Bresnihan, B, De Benedetti, F, Dorner, T, Gibofsky, A, Schiff, M H, Sieper, J, Singer, N, Van Riel, P L C M, Weinblatt, M E, Weisman, M H (2008). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67: iii2-iii25 [Full Text]  
• Simonini, G., Zannin, M. E., Caputo, R., Falcini, F., de Martino, M., Zulian, F., Cimaz, R. (2008). Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology (Oxford) 47: 1510-1514 [Abstract] [Full Text]  
• Tynjala, P., Kotaniemi, K., Lindahl, P., Latva, K., Aalto, K., Honkanen, V., Lahdenne, P. (2008). Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 47: 339-344 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Sieper, J, Emery, P, Keystone, E C, Schiff, M H, Mease, P, van Riel, P L C M, Fleischmann, R, Weisman, M H, Weinblatt, M E (2007). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66: iii2-iii22 [Full Text]  
• Gallagher, M., Quinones, K., Cervantes-Castaneda, R. A., Yilmaz, T., Foster, C S. (2007). Biological response modifier therapy for refractory childhood uveitis. Br. J. Ophthalmol. 91: 1341-1344 [Abstract] [Full Text]  
• Mansour, A. M (2007). Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol. 91: 274-276 [Full Text]